BioSpace News Archive

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Zogenix, a global biopharmaceutical company developing and commercializing rare disease therapies, announced financial results for the three months ended March 31, 2021, and provided a corporate update.

Y-mAbs Therapeutics, Inc. a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, reported financial results for the first quarter of 2021.

Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, announced financial results for the first quarter ended March 31, 2021 and provided a business update.

Neovasc, Inc., reported financial results for the first quarter ended March 31, 2021.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

Accelerate Diagnostics, Inc. announced financial results for the first quarter for the period ended March 31, 2021.

BioLife Solutions, Inc., a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, announced that the Company’s first quarter 2021 financial results will be released after market close on Thursday, May 13, 2021, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ to treat serious neurologically mediated conditions, announced that management will host a conference call and live audio webcast on Thursday, May 13 at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the quarter ended March 31, 2021.

Nephros, Inc., a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, announced results for the three months ended March 31, 2021.